Condition: Non-Hodgkin Lymphoma, B-cell · Sponsor: Ryvu Therapeutics SA
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
This description comes directly from the study's public registry record.
Head of Clinical Operations · +48 123140200 · clinicaltrials@ryvu.com
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Le Mans | Le Mans, France | Recruiting |
| CHU de Lille - Hôpital Claude Huriez | Lille, France | Recruiting |
| CHU de Limoges - CHU Dupuytren | Limoges, France | Recruiting |
| Hospices Civils De Lyon - Hôpital Lyon Sud | Lyon, France | Recruiting |
| CHU Montpellier - Hôpital Saint Eloi | Montpellier, France | Recruiting |
| APHP - Hôpital Pitié-Salpêtrière | Paris, France | Recruiting |
| CHU de Bordeaux - Hôpital Haut-Lévêque | Pessac, France | Recruiting |
| Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej | Biała Podlaska, Poland | Recruiting |
| IN-VIVO Bydgoszcz Sp. z o.o. | Bydgoszcz, Poland | Recruiting |
| Klinika Hematologii I Transplantologii Uck | Gdansk, Poland | Not Yet Recruiting |
| Szpitale Pomorskie Sp. z o.o. | Gdynia, Poland | Recruiting |
| Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy | Gliwice, Poland | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06534437